Articles tagged with Cancer Genome Sequencing
A study identified significant differences in cancer genome sequencing procedures and quality among research institutions, leading to inconsistencies in detected mutations. A reference mutation dataset has been established to improve procedures for identifying true somatic mutations in cancer genomes.
Researchers analyzed genomic data from 1,120 pediatric cancer patients and found that 8.5% had pathogenic germline mutations in cancer predisposition genes. This study suggests that comprehensive genomic screening may be necessary for all pediatric cancer patients, not just those with a family history of cancer.
The San Antonio 1000 Cancer Genomes Project has partnered with WuXi NextCODE to utilize its CLIA sequence laboratory and HIPAA-compliant secondary analysis solution. This partnership enables the project to link genetic alterations to detailed clinical outcomes, making data freely available worldwide.
Individualized medicine is revolutionizing patient care through precision diagnostics, such as preventing drug-related adverse effects and identifying disease susceptibility. Whole exome sequencing is also offering new diagnoses for patients with undiagnosed diseases.
A new UCLA study reveals that Alzheimer's disease consists of three distinct subtypes, each requiring targeted research and potential new treatments. The cortical subtype appears to be fundamentally different from the other two, suggesting different causes and optimal treatment approaches.
A study published in JAMA found that incorporating genomic sequencing and counseling into pediatric cancer treatment improved patient outcomes and changed treatment plans. The study showed that nearly half of patients had actionable findings that led to individualized actions, including genetic counseling and changes in treatment.
Two California Initiative to Advance Precision Medicine projects aim to treat pediatric cancer with genetic analysis and diagnose acute infections using DNA sequencing. The projects, led by UCSF researchers, have the potential to deliver precision medicine tests and therapies within 18-24 months.
Studies of oesophageal tumour samples reveal that L1 elements can alter cell growth and division, potentially leading to cancer. Mobile genetic sequences are found to occur around 100 times in each tumour sample, with some occurring up to 700 times.
Researchers found that genomic mutations in the TP53, APC, and CDKN2A genes were present in 75% of progressors with Barrett's esophagus. This ability to detect mutations in non-neoplastic mucosa can improve early detection and surveillance for patients at heightened risk for esophageal cancer.
A global challenge has led to the development of a new benchmark for analyzing cancer genomes, with ensemble algorithms demonstrating superior accuracy. The study highlights the importance of combining multiple approaches and optimizing parameters to improve mutation detection accuracy.
A study suggests that sequencing tumor genomes without comparing them to a patient's noncancerous tissue can lead to inaccurate treatment decisions and side effects. The researchers analyzed over 800 cancer patients' data, finding that nearly half of the identified genetic changes were not related to the cancer.
Researchers and clinicians can design studies, create personalized treatment plans, and inform medical decisions with accurate genomic data. The NYC-CDRN aggregates over six million patients' medical data to study patterns and trends in cancer across a large patient population.
A new gene sequencing technology, CaptureSeq, enables accurate measurement of specific genes' activity at minute levels, improving blood cancer diagnosis. The technology has practical applications in diagnosing diseases guided by gene expression.
Scientists from RIKEN have found that chronic hepatitis infection and inflammation can lead to similar genetic mutations in liver tumors, potentially paving the way for targeted therapies. The study identified changes in mutations associated with aggressive biliary-type liver cancers and discovered new targets for future treatments.
A collaboration between St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and Institut Curie-Inserm identified frequent mutations in genes STAG2 and TP53 that define a subtype of Ewing sarcoma associated with reduced survival. The study provides critical insights into the genetic changes that d...
Research identifies RAS oncogene involvement in DS-ALL cases, highlighting genetic insights into leukemia risk in children with Down syndrome. Geneticists sequenced exomes of affected individuals, shedding light on disease characteristics.
Researchers used molecular tumor boards to evaluate 34 patients with advanced cancer, identifying 74 genes and 123 aberrations involved in cancer growth. The approach showed promise in tailoring personalized treatment plans for patients who have exhausted standard therapies.
The study found that HPV disrupts host-cell genes and chromosomes at sites of viral insertion, leading to overexpression or disruption of cancer-causing genes. This damage promotes the development of cancer by increasing the expression of viral E6 and E7 proteins.
Researchers propose a new approach to understanding biology, shifting focus from genes to energy consumption and complex dissipative systems. The theory suggests that genes cannot determine biological activity, but rather, it is the energy flows within cells that drive emergence of properties.
Researchers at Simon Fraser University have discovered that non-coding RNAs are perturbed in cancerous human cells, allowing for early detection of breast and lung cancers. The study's findings suggest that these molecules can be used to classify patients into subgroups with different survival outcomes.
The genome of the world's oldest continuously surviving cancer, a transmissible genital cancer in dogs, has been sequenced. The cancer carries about two million mutations and is believed to have arisen 11,000 years ago. Analysis reveals that the cancer still harbors genetic variants from its ancient host.
Researchers discovered a genetic signature that implicates key immune system mechanism in driving acute lymphoblastic leukemia, the most common form of childhood cancer. The study found that genomic rearrangement and deletions of DNA segments drive cancer progression.
A new survey of nearly 5,000 tumor samples has identified 140 regions with scrambled genetic code believed to contain many undiscovered cancer genes. The mapping gives researchers a starting point to search for oncogenes and tumor-suppressor genes.
A study published in Genome Medicine has identified a specific subtype of pancreatic cancer that expresses high levels of the HER2 gene, which could be treated with existing breast and gastric cancer therapies. The research suggests using personalized medicine strategies to target this subtype, potentially improving patient outcomes.
A new bioinformatics software tool, DrGaP, has been developed to identify genetic mutations responsible for cancers. The tool combines statistical methods and bioinformatics tools to distinguish between driver mutations and passenger mutations, leading to a more complete identification of altered genes and signaling pathways in cancer.
Aristolochic acid, a plant compound in herbal remedies, causes upper urinary tract cancers through a distinct DNA mutational signature. The Johns Hopkins and Stony Brook study used whole-exome sequencing to identify this signature, which was found in 19 Taiwanese cancer patients exposed to the toxin.
A large-scale analysis reveals many common cancers are not associated with DNA viruses, contradicting earlier estimates. The study highlights the importance of bioinformatics in understanding virus integration into cancer subtypes.
The NIH has awarded four new grants to explore the use of genome sequencing in medical care, including informing couples about reproductive risks and detecting genomic alterations that can lead to cancer. The grants total approximately $6.7 million in the first year and aim to advance treatment and improve patient outcomes.
Bioethicists argue that patients should not be forced to receive genomic information about future health risks without their consent. The ACMG recommendations on reporting incidental findings in clinical genome sequencing are seen as problematic due to concerns over patient autonomy and cost implications.
Researchers at A*STAR's Genome Institute of Singapore discovered four processes that cause mutations in gastric cancer, including one triggered by bacterial infection. These findings pave the way for diagnostics and targeted therapy, with potential implications for improving treatment outcomes.
A new approach to analyzing repetitive DNA at chromosome ends has revealed potential cancer clues, including a link between telomere length and genetic mutations. The study found that 32% of pediatric solid tumors carried extra DNA for telomeres, compared to brain tumors and leukemia samples.
Researchers created a genomic sequencing test, 'PapGene', using cervical fluid from routine Pap tests to detect ovarian and endometrial cancers with high accuracy. The test distinguished cancerous DNA from normal DNA, detecting both early and late-stage diseases.
A study by TGen and US Oncology Research identified genetic mutations in 14 metastatic TNBC patients, including TP53 and ERBB4 tumor suppressor genes. The research offers potential drug targets for this aggressive form of breast cancer.
Researchers at Johns Hopkins Kimmel Cancer Center have created a test that combines blood DNA analysis with genome sequencing to detect cancers. The new approach was successful in identifying cancer-specific chromosome changes in the blood of patients, but may require larger clinical trials to determine its effectiveness.
The study identified mutations in genes involved in chromatin modification and axon guidance, which are not previously linked to pancreatic cancer. New information on these genes could lead to exciting treatment strategies for the disease.
A new $13 million project at Fred Hutchinson Cancer Center aims to identify genetic links to colorectal cancer using next-generation sequencing. The study will reveal entire genome sequences of a subset of samples and capture rare variants that could lead to improved drug development and disease prevention.
Researchers aims to develop parallel strategies for protein identification in complex mixtures with potential applications in cancer diagnosis and biomarker discovery. The project builds on existing networks that analyze genetic data and identify potential relationships among genes and proteins.
Researchers have characterized the lung squamous cell carcinoma genome, identifying commonly known cancer genes and mutations that could be targeted therapeutically. The study, led by UNC Lineberger scientists, paves the way for developing better, more targeted treatments for this devastating disease.
Dr. Ley's work on whole genome sequencing in AML has provided unprecedented insights into the disease, highlighting the importance of unbiased methods for discovering cancer-initiated mutations. His research also revealed that most AML mutations are benign background events, with only a handful contributing to pathogenesis.
Researchers at Mayo Clinic have completed the world's first genome-wide sequencing analysis of peripheral T-cell lymphomas, unlocking genetic secrets of this poorly understood and highly aggressive cancer. The study identifies 13 genomic abnormalities, including five related to production and behavior of the p53 protein.
Researchers have discovered a new target for treating acute myeloid leukemia by targeting cyclin-dependent kinase 1 (CDK1), which promotes differentiation of cancer cells. Additionally, inflammation has been found to play a significant role in age-related retinal degeneration.
Researchers at UC San Diego mapped nearly 300,000 mouse cis-regulatory elements, annotating 11% of the mouse genome and identifying conserved non-coding sequences shared with humans. The study provides insights into the functional organization of genes and their regulation in different tissues and cell types.
The St. Jude Children's Research Hospital has released the world's largest comprehensive human cancer genome data, exceeding volume of all other sources combined. This valuable information is available for free access by researchers, accelerating disease research and potentially leading to new treatment options for childhood cancers.
A study conducted by TGen-Scottsdale Healthcare analyzed the patient's tumor and normal DNA to identify significant gene mutations that could be targeted for therapy. The analysis provided clues to possible precision medicine treatment of rare nasal tract cancer.
A team of researchers at the Wellcome Trust Sanger Institute sequenced the genomes of 21 breast cancers, revealing new mutation processes that drive their development. The study found that these mutations accumulate over time, creating a complex landscape of genetic changes in the cancer cells.
A team of scientists has sequenced the whole genomes of 25 metastatic melanoma tumors, confirming the role of chronic sun exposure and revealing new genetic changes. The study identified a gene called PREX2, which is mutated in 44% of patients and appears to accelerate tumor development.
A Johns Hopkins study of thousands of identical twins found that whole genome sequencing is not informative for predicting most common diseases. While the test can alert individuals to an increased risk of certain diseases, it fails to forewarn them of others they may ultimately develop.
Scientists at WashU Medicine are using DNA sequencing to map the genetic evolution of disease and monitor response to treatment. By analyzing tumor samples, they can identify 'driver' mutations and determine whether cells carrying those mutations have been eliminated by treatment.
Researchers sequenced DNA from cancer cells in patients with myelodysplastic syndromes who later developed leukemia, finding that the disease is an early form of cancer. The study suggests that targeted cancer drugs should be aimed at mutations that develop early in the disease.
Professor Mike Stratton discusses the evolution of the cancer genome at the AAAS annual meeting, highlighting advances in whole genome sequencing and the development of COSMIC catalogue. This research provides insights into cancer causation, prevention, and treatment, with potential global solutions through international collaboration.
Researchers sequenced the Tasmanian devil cancer genome to understand its origin and spread. The study found that the cancer arose from a single female Tasmanian devil and has genetically diverged during its spread, indicating some sub-types may be more virulent.
Researchers sequenced the complete genome of an immortal Tasmanian devil and its transmissible cancer, providing insights into how the disease spread rapidly through the population. The study identified over 17,000 mutations in the cancer genome, which may lead to therapeutic strategies against cancer genes.
The study identified biologically relevant targets in breast cancer using mRNA sequencing, revealing novel and unannotated transcripts. The GW research team discovered common and differentially expressing transcripts between three types of breast cancer, shedding light on the disease's underlying mechanisms.
A new algorithm, R-SAP, transforms complex RNA sequence data into usable content for biologists and clinicians, enabling personalized cancer medicine. The pipeline accurately characterizes gene transcripts in cancer samples and provides information on splice variants, biomarkers, and chimeric RNAs.
Researchers have uncovered new genetic evidence supporting the hypothesis that acral melanoma is a distinct subtype with UV-damage signatures. Whole-exome sequencing of pancreatic cancer cell lines revealed a significant correlation between loss of MLH1 gene and indel mutation rates, disrupting several well-known cancer genes.
Researchers found a strong link between an inherited TP53 gene mutation and chromothripsis, a condition where chromosomes shatter and reassemble incorrectly. This discovery has significant implications for diagnosis and treatment, as patients with the mutation may be at high risk of developing certain types of cancer.
Researchers have discovered a genetic connection between two cancers, one with poor prognosis and the other with better outcomes. The study suggests that patients with the more aggressive cancer may benefit from treatment developed for acute myeloid leukemia.
Researchers found that chemotherapy can lead to DNA damage in cancer cells, which can cause them to evolve and become resistant to treatment. The study suggests that targeted therapies based on individual mutations may be more effective than current treatments.
The study analyzed over 300 tumor samples and found that 96% had mutated TP53 genes, while BRCA1 and BRCA2 were mutated in 30% of patients. The researchers identified a set of genes associated with worse or better patient outcomes, predicting survival rates.
Researchers use genome sequencing and analysis to identify individuals for captive breeding programs, aiming to maximize genetic diversity and prevent extinction. The study provides insights into the impact of European settlement on Tasmanian devil genomic diversity.